Anthony Heaney, MD
Endocrinology, Diabetes & Metabolism · Los Angeles, CANPI 1720016850
Payments from drug & device makers
Across 532 payments — averaging $1482.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$209K
- Novo Nordisk$156K
- Strongbridge US Inc.$94K
- Amryt Pharma Holdings Ltd$86K
- Ascendis Pharma Endocrinology Inc$75K
- Recordati_rare_diseases_inc.$69K
- plus $100K from 11 others
Across 5 payments — averaging $8963.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amryt Pharma Holdings Ltd$39K
- Chiasma, Inc.$6K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 182 | $209,083 |
| Novo Nordisk | 122 | $155,664 |
| Strongbridge US Inc. | 16 | $93,714 |
| Amryt Pharma Holdings Ltd | 68 | $85,793 |
| Ascendis Pharma Endocrinology Inc | 7 | $74,924 |
| Recordati_rare_diseases_inc. | 51 | $69,296 |
| Chiesi USA, Inc. | 32 | $30,981 |
| Chiasma, Inc. | 21 | $27,450 |
| Xeris Pharmaceuticals, Inc. | 6 | $14,846 |
| Ipsen Biopharmaceuticals, Inc | 17 | $14,416 |
| Pfizer | 2 | $7,094 |
| Progenics Pharmaceuticals, Inc. | 1 | $1,842 |
| H. Lundbeck A S | 1 | $1,200 |
| Sun Pharmaceutical Industries Inc. | 1 | $1,016 |
| Tolmar, Inc. | 3 | $603 |
| Novo Nordisk US Research & Development, Inc. | 1 | $500 |
| Curium US LLC | 1 | $17 |
How this compares
$788,440 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Los Angeles
- Stanley HsiaLos Angeles$19.8M
- Shlomo MelmedLos Angeles$3.3M
- Sina TebiLos Angeles$2.4M
- Christian GastelumLos Angeles$421K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.